Is homocysteine an iron-dependent cardiovascular risk factor?

Kidney International

Volumn 69, Issue 4, 2006, Pages 642-644

  Sullivan, J L ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; IRON; METHIONINE; RAZOXANE;

CARDIOVASCULAR RISK; CHELATION; CLINICAL TRIAL; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASCULAR DISEASE;

EID: 32544450350     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000229     Document Type: Note

References (18)

1. Sullivan JL Iron and the sex difference in heart disease risk. Lancet 1981; 1: 1293-1294.
2. Sullivan JL. Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am. Heart J 2004; 145: 190-194.
3. Boers GH, Smals AG, Trijbels FJ et al. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983; 72: 1971-1976
4. Fukagawa NK, Martin JM, Wurthmann A et al. Sex-related differences in methionine metabolism and plasma homocysteine concentrations. Am J Clin Nutr 2000; 72: 22-29
5. Masse PG, Dosy J, Cole DE et al. Elevation of plasma homocysteine in natural menopause can not be explained by a lack of vitamin coenzyme availability: relevance to the risk of cardiovascular disease. J Nutr Health Aging 2005; 9: 59-64
6. Suh JR, Oppenheim EW, Girgis S et al. Purification and properties of a folate-catabolizing enzyme. J Biol Chem 2000; 275: 35646-35655
7. Suh JR, Herbig AK, Stover PJ. New perspectives on folate catabolism. Annu Rev Nutr 2001; 21: 255-282
8. Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med 2005; 5: 215-222
9. Bonaa KH. NORVIT: Randomised trial of homocysteine-lowering with B vitamins for secondary prevention of cardiovascular disease after acute myocardial infarction. (abstract). European Society of Cardiology September 2005 Conference 2005
10. Zheng H, Huang X, Zhang Q et al. Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int 2006; 69: 679-684
11. Zheng H, Dimayuga C, Hudaihed A et al. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arterioscler Thromb Vasc Biol 2002; 22: E15-E18
12. Zheng H, Cable R, Spencer B et al. Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol 2005; 25: 1577-1583
13. Sullivan JL Stored iron and vascular reactivity. Arterioscler Thromb Vasc Biol 2005; 25: 1532-1535
14. Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci 2002; 967: 342-351
15. van Guldener C, Stehouwer CD. Homocysteine and methionine metabolism in renal failure. Semin Vasc Med 2005; 5: 201-208
16. Sullivan J. Is stored iron safe? J Lab Clin Med 2004; 144: 280-284
17. Ferrara DE, Taylor WR. Iron chelation and vascular function: in search of the mechanisms. Arterioscler Thromb Vasc Biol 2005; 25: 2235-2237
18. Yuan XM, Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann. Med. 2005; 35: 578-591